Court Permits Pfizer Robitussin MS Anti-Cough Drug Class Action To Push On 

The class action against the drug manufacturer Pfizer that is accusing it of knowingly tricking its buyers into thinking that they are buying a more potent cough syrup (Maximum Strength Robitussin Anti-Cough Syrup), although it only has a lower ingredients concentration, is allowed to move forward.

‘Maximum Strength’ Claims In Robitussin Drug Is Misleading

Although Pfizer has done a lot to have the charges dropped, the court decided that the legal merits of the Robitussin Maximum Strength Cough Syrup Class Action Lawsuit are permitted. 

Penned by United States (U.S.) District Judge J. Paul Oetken, the decision said that Pfizer’s argument that everyday customers can cross-check and examine the ingredients between like drugs to compare their substance concentration is not reasonable enough. 

Additionally, the judge upheld that the customers allegedly duped into buying the ‘Maximum Strength’ Robitussin anti-cough medication have suffered from monetary loss despite Pfizer’s counterarguments. 

The Timothy Woodhams, et al. v. Pfizer Inc. Legal Case

The Robitussin Maximum Strength Cough Syrup Class Action Lawsuit is a legal case launched against the medicine industry behemoth by complainants Timothy Woodhams and Karmel Al-Haj. 

Originally filed in an Illinois-based federal court, the first iteration of the legal accusations did not prosper due to the lack of personal jurisdiction of one of the plaintiffs. 

Now, the Robitussin Maximum Strength Cough Syrup Class Action Lawsuit legal challenge is filed and being processed in New York. Woodhams and his peers want to form and represent a Class group consisting of Pfizer Maximum Strength Robitussin anti-cough medication buyers who were reportedly made to think that they are buying a more potent drug.

Consider The Consumer will continue to update you with the latest news about this matter.  

Editor’s Note on Robitussin Maximum Strength Cough Syrup Class Action Lawsuit: 

This feature aims to give you an update on the recent case developments surrounding Pfizer’s Robitussin cough drug and the allegations thrown against it. A similar lawsuit was also filed against Zarbees Nighttime Syrup.

Case Name(s) & No.(s): Timothy Woodhams, et al. v. Pfizer Inc.; Case No.: 1:18-cv-03990

Jurisdiction: United States (U.S.) District Court for the Southern District of New York 

Allegation(s): Robitussin ‘Maximum Strength’ contains less potent substances despite the marketing claims trying to point out otherwise.        

What are your thoughts on this piece? Please send us a message by clicking the ‘Contact Us’ button below! We’d love to hear back from you.

Contact Us

You can also reach out to us on Twitter or Facebook or via email at Outreach@ConsiderTheConsumer.com. Also, directly on our website! We look forward to hearing from you.